Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
1.
J Pediatr ; 268: 113934, 2024 May.
Article in English | MEDLINE | ID: mdl-38309519

ABSTRACT

OBJECTIVE: The objective of this study was to determine if valganciclovir initiated after 1 month of age improves congenital cytomegalovirus-associated sensorineural hearing loss. STUDY DESIGN: We conducted a randomized, double-blind, placebo-controlled phase 2 trial of 6 weeks of oral valganciclovir at US (n = 12) and UK (n = 9) sites. Patients of ages 1 month through 3 years with baseline sensorineural hearing loss were enrolled. The primary outcome was change in total ear hearing between baseline and study month 6. Secondary outcome measures included change in best ear hearing and reduction in cytomegalovirus viral load in blood, saliva, and urine. RESULTS: Of 54 participants enrolled, 35 were documented to have congenital cytomegalovirus infection and were randomized (active group: 17; placebo group: 18). Mean age at enrollment was 17.8 ± 15.8 months (valganciclovir) vs 19.5 ± 13.1 months (placebo). Twenty (76.9%) of the 26 ears from subjects in the active treatment group did not have worsening of hearing, compared with 27 (96.4%) of 28 ears from subjects in the placebo group (P = .09). All other comparisons of total ear or best ear hearing outcomes were also not statistically significant. Saliva and urine viral loads decreased significantly in the valganciclovir group but did not correlate with change in hearing outcome. CONCLUSIONS: In this randomized controlled trial, initiation of antiviral therapy beyond the first month of age did not improve hearing outcomes in children with congenital cytomegalovirus-associated sensorineural hearing loss. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01649869.


Subject(s)
Antiviral Agents , Cytomegalovirus Infections , Ganciclovir , Hearing Loss, Sensorineural , Valganciclovir , Humans , Cytomegalovirus Infections/drug therapy , Cytomegalovirus Infections/congenital , Cytomegalovirus Infections/complications , Valganciclovir/therapeutic use , Valganciclovir/administration & dosage , Hearing Loss, Sensorineural/drug therapy , Hearing Loss, Sensorineural/virology , Hearing Loss, Sensorineural/etiology , Antiviral Agents/therapeutic use , Antiviral Agents/administration & dosage , Male , Female , Double-Blind Method , Infant , Administration, Oral , Ganciclovir/analogs & derivatives , Ganciclovir/therapeutic use , Ganciclovir/administration & dosage , Child, Preschool , Treatment Outcome , Viral Load , Infant, Newborn
2.
SAGE Open Med Case Rep ; 10: 2050313X221128388, 2022.
Article in English | MEDLINE | ID: mdl-36210865

ABSTRACT

A diagnosis of multisystem inflammatory syndrome in children should be made in the appropriate context and after ruling out other infectious causes. At the same time, clinicians should be diligent as the initial presentation can be unusual and the clinical picture can evolve over time. We report a case that was initially diagnosed as a retropharyngeal infection that did not improve on appropriate antimicrobial coverage. However, as the clinical picture evolved, the patient was found to have multisystem inflammatory syndrome in children and appropriately responded to immunomodulatory treatment. Pediatric infectious diseases practice has been significantly affected by the COVID-19 virus and multisystem inflammatory syndrome in children; data are still emerging as the pandemic evolves. We report this case and conduct literature review to expand the body of evidence about the association between multisystem inflammatory syndrome in children and retropharyngeal involvement.

3.
R I Med J (2013) ; 103(6): 47-48, 2020 Aug 03.
Article in English | MEDLINE | ID: mdl-32752567

ABSTRACT

The danger of vaccine hesitancy is perhaps one of the most critical challenges we face as practitioners. This riveting narrative helps us find common ground and courage as it reaches into the hearts of those of us who have encountered parents who also want what's best for their child.


Subject(s)
Health Knowledge, Attitudes, Practice , Immunization/psychology , Patient Acceptance of Health Care , Vaccines/administration & dosage , Adolescent , Child , Child, Preschool , Humans , Infant , Infant, Newborn , Parents , Physicians
4.
Hosp Pediatr ; 8(7): 385-393, 2018 07.
Article in English | MEDLINE | ID: mdl-29946040

ABSTRACT

BACKGROUND: Systems for standardizing physician payment have been shown to undervalue cognitive clinical encounters. Because health care reform emphasizes value-based approaches, we need an understanding of the way pediatric cognitive specialties are used to contribute to the provision of high-value care. We sought to investigate how clinical and administrative stakeholders perceive the value of pediatric infectious disease (PID) specialists. METHODS: We conducted qualitative interviews with a purposive sample of physicians and administrators from 5 hospitals across the United States in which children are cared for. All interviews were transcribed and systematically analyzed for common themes. RESULTS: We interviewed 97 stakeholders. Analysis revealed the following 3 domains of value: clinical, organizational, and communicative. Clinically, PID specialists were perceived to be highly valuable in treating patients with unusual infections that respond poorly to therapy, in optimizing the use of antimicrobial agents and in serving as outpatient homes for complex patients. Respondents perceived that PID specialists facilitate communication with patients and their families, the health care team and the media. PID specialists were perceived to generate value by participating in systemwide activities, including antimicrobial stewardship and infection prevention. Despite this, much of the valuable work PID specialists perform is difficult to measure causing some administrative stakeholders to question how many PID specialists are necessary to achieve high-quality care. CONCLUSIONS: With our findings, we suggest that pediatric cognitive specialties contribute value in multiple ways to the health care delivery system. Many of these domains are difficult to capture by using current metrics, which may lead administrators to overlook valuable work and to under-allocate resources.


Subject(s)
Delivery of Health Care/economics , Physicians/economics , Reimbursement Mechanisms/statistics & numerical data , Specialization/economics , Child , Delivery of Health Care/standards , Fee-for-Service Plans , Fees, Medical , Humans , Models, Economic , Physicians/standards , Qualitative Research , Reference Standards , United States
5.
Pediatr Infect Dis J ; 37(1): e13-e19, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28834957

ABSTRACT

BACKGROUND: In February 2015, two unlinked culture-confirmed cases of Neisseria meningitidis serogroup B (MenB) disease occurred at a local college in Rhode Island ("college X") within 3 days. This represented a 489-fold increase in the incidence of MenB disease, and an outbreak was declared. For the first time, bivalent rLP2086 (Trumenba) was selected as a mandatory intervention response. A mass vaccination clinic was coordinated, which provided a unique opportunity to collect safety data in a real-world population of college-age participants. Though the Advisory Committee on Immunization Practices recommends MenB vaccination for college-age individuals (16-23 year olds), there is limited quantifiable safety data available for this population. METHODS: The Dillman total design survey method was used. Adverse events of bivalent rLP2086 were solicited and quantified retrospectively 2-4 months following each dose of vaccine. Safety data from six clinical trials were used as comparison tools. RESULTS: The most commonly reported adverse event following vaccination was injection site pain. Reported rates of injection site pain, fatigue, myalgia, fever, and chills were similar than those reported in clinical trials. Reported rates of headache were lower than in clinical trials. CONCLUSIONS: This study is the first to examine adverse events of bivalent rLP2086 in a real-world setting where more than 90% of a college-age population was vaccinated.


Subject(s)
Disease Outbreaks/prevention & control , Drug-Related Side Effects and Adverse Reactions/epidemiology , Mass Vaccination/adverse effects , Meningitis, Meningococcal/prevention & control , Meningococcal Vaccines/adverse effects , Adolescent , Adult , Antigens, Bacterial , Bacterial Proteins , Disease Outbreaks/statistics & numerical data , Female , Humans , Longitudinal Studies , Male , Mass Vaccination/statistics & numerical data , Meningitis, Meningococcal/epidemiology , Meningococcal Vaccines/administration & dosage , Rhode Island/epidemiology , Young Adult
6.
Pediatr Infect Dis J ; 37(7): 654-661, 2018 07.
Article in English | MEDLINE | ID: mdl-29280786

ABSTRACT

BACKGROUND: Vancomycin is frequently used to treat methicillin-resistant Staphylococcus aureus infections in pediatric patients. Vancomycin exposure may lead to an increase in frequency of nephrotoxicity. Our aim was to conduct a systematic review to describe predictors of nephrotoxicity associated with vancomycin, including documented trough concentrations ≥15 mg/L. We also aimed to use a meta-analysis to assess the impact of a vancomycin trough ≥15 mg/L on nephrotoxicity. METHODS: A literature search was performed using PubMed, Cochrane Library, Embase and Web of Sciences database. We included randomized clinical trials and observational studies evaluating the relationship between vancomycin troughs and nephrotoxicity in pediatric-age patients. Studies not measuring troughs or defining a different cut-off point than 15 mg/L were excluded. Data on age, exclusion criteria, nephrotoxicity definition, risk factors for nephrotoxicity and vancomycin trough levels were extracted from selected papers. RESULTS: Ten studies were identified for meta-analysis. All subjects had comparatively normal baseline serum creatinine values. Common risk factors identified included elevated (≥15 mg/L) trough levels, renal impairment, hypovolemia and concurrent use of nephrotoxic medications. Troughs ≥15 mg/L increased nephrotoxicity by 2.7-fold (odds ratio (OR), 2.71; 95% confidence interval: 1.82-4.05; I(2) = 40%; Q = 0.09). These odds were further increased among patients in the pediatric intensive care unit (OR, 3.61; 95% confidence interval: 1.21-10.74; I(2) = 45%; Q = 0.18). CONCLUSIONS: Though the rate of vancomycin-induced nephrotoxicity is increased in pediatric patients with higher vancomycin troughs, other factors such as intensive care unit admission, hypovolemia and concurrent nephrotoxic drug use appear to contribute to the development of nephrotoxicity.


Subject(s)
Anti-Bacterial Agents/toxicity , Kidney Diseases/chemically induced , Kidney/drug effects , Vancomycin/toxicity , Child , Humans , Intensive Care Units , Kidney/microbiology , Kidney/pathology , Methicillin-Resistant Staphylococcus aureus/drug effects , Observational Studies as Topic , Odds Ratio , Randomized Controlled Trials as Topic , Retrospective Studies , Risk Factors , Staphylococcal Infections/drug therapy
8.
R I Med J (2013) ; 100(2): 34-38, 2017 Feb 01.
Article in English | MEDLINE | ID: mdl-28146598

ABSTRACT

BACKGROUND: Refugee populations in the US have a higher reported prevalence of latent tuberculosis infection (LTBI). The objective of this study was to assess adherence to LTBI treatment in refugee and non-refugee children living in Rhode Island. METHODS: This was a retrospective review of LTBI patients seen in the Hasbro Pediatric Tuberculosis Clinic between August 2009 and September 2011. RESULTS: Of 120 patients with LTBI, 93% were foreign-born and 30% were refugees. Overall, 94 children (78.3%) completed therapy. Higher rates of treatment completion were seen among patients who were female, referred within the same hospital system, used an interpreter, and did not report side effects. Refugees attended more scheduled visits compared to non-refugees (p=0.019). CONCLUSIONS: Overall rates of completion of LTBI treatment were high in this population. Better adherence to clinic visits, likely due to the increased support and care coordination provided to the refugee children, improved treatment completion rates. [Full article available at http://rimed.org/rimedicaljournal-2017-02.asp].


Subject(s)
Antitubercular Agents/therapeutic use , Latent Tuberculosis/drug therapy , Latent Tuberculosis/epidemiology , Medication Adherence/statistics & numerical data , Refugees , Adolescent , Ambulatory Care Facilities , Appointments and Schedules , Child , Child, Preschool , Female , Humans , Infant , Latent Tuberculosis/prevention & control , Male , Retrospective Studies , Rhode Island/epidemiology
9.
J Am Coll Health ; 65(4): 294-296, 2017.
Article in English | MEDLINE | ID: mdl-28121236

ABSTRACT

OBJECTIVE: To outline the reasoning behind use of bivalent rLP2086 in a Rhode Island college meningococcal B disease outbreak, highlighting the timeline from outbreak declaration to vaccination clinic, emphasizing that these two time points are <3 days apart. PARTICIPANTS: Staff, faculty, and students at College X eligible for vaccination. METHODS: An outbreak response was initiated, advantages/disadvantages of available MenB vaccines were discussed, and a vaccination clinic was coordinated. RESULTS: Bivalent rLP2086 was chosen as the vaccination intervention. We achieved a 94% coverage rate for the first dose. To date, this intervention has prevented further cases of Neisseria meningitidis serogroup B disease at College X. CONCLUSIONS: The close, efficient collaboration of public health stakeholders and College X led 94% of the eligible population to be safely vaccinated with at least one dose of bivalent rLP2086. This outbreak marked the first time bivalent rLP2086 was effectively used as an intervention response.


Subject(s)
Civil Defense/organization & administration , Disease Outbreaks , Meningococcal Vaccines/therapeutic use , Universities/trends , Antigens, Bacterial/pharmacology , Antigens, Bacterial/therapeutic use , Bacterial Proteins/pharmacology , Bacterial Proteins/therapeutic use , Civil Defense/methods , Faculty/statistics & numerical data , Humans , Meningococcal Infections/drug therapy , Meningococcal Infections/epidemiology , Meningococcal Infections/immunology , Meningococcal Vaccines/pharmacology , Neisseria meningitidis, Serogroup B/pathogenicity , Public Health/methods , Public Health/trends , Rhode Island/epidemiology , Students/statistics & numerical data , Universities/statistics & numerical data
11.
J Pediatric Infect Dis Soc ; 5(1): 53-62, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26407253

ABSTRACT

BACKGROUND: Neonatal enterovirus sepsis has high mortality. Antiviral therapy is not available. METHODS: Neonates with suspected enterovirus sepsis (hepatitis, coagulopathy, and/or myocarditis) with onset at ≤15 days of life were randomized 2:1 to receive oral pleconaril or placebo for 7 days. Serial virologic (oropharynx, rectum, urine, serum), clinical, pharmacokinetic, and safety evaluations were performed. RESULTS: Sixty-one subjects were enrolled (43 treatment, 18 placebo), of whom 43 were confirmed enterovirus infected (31 treatment, 12 placebo). There was no difference in day 5 oropharyngeal culture positivity (primary endpoint; 0% in both groups). However, enterovirus-infected subjects in the treatment group became culture negative from all anatomic sites combined faster than placebo group subjects (median 4.0 versus 7.0 days, P = .08), and fewer subjects in the treatment group remained polymerase chain reaction (PCR)-positive from the oropharynx when last sampled (23% versus 58%, P = .02; median, 14.0 days). By intent to treat, 10/43 (23%) subjects in the treatment group and 8/18 (44%) in the placebo group died (P = .02 for 2-month survival difference); among enterovirus-confirmed subjects, 7/31 (23%) in the treatment group died versus 5/12 (42%) in the placebo group (P = .26). All pleconaril recipients attained concentrations greater than the IC90 after the first study day, but 38% were less than the IC90 during the first day of treatment. One subject in the treatment group and three in the placebo group had treatment-related adverse events. CONCLUSIONS: Shorter times to culture and PCR negativity and greater survival among pleconaril recipients support potential efficacy and warrant further evaluation.


Subject(s)
Antiviral Agents/therapeutic use , Enterovirus Infections/complications , Enterovirus Infections/drug therapy , Enterovirus/drug effects , Neonatal Sepsis/drug therapy , Neonatal Sepsis/virology , Oxadiazoles/therapeutic use , Antiviral Agents/blood , Antiviral Agents/pharmacokinetics , Antiviral Agents/urine , Double-Blind Method , Enterovirus/genetics , Enterovirus/isolation & purification , Enterovirus Infections/blood , Enterovirus Infections/urine , Female , Humans , Infant , Infant, Newborn , Male , Neonatal Sepsis/blood , Neonatal Sepsis/urine , Oropharynx/virology , Oxadiazoles/blood , Oxadiazoles/pharmacokinetics , Oxadiazoles/urine , Oxazoles , Rectum/virology
12.
Infect Dis Clin North Am ; 29(4): 617-35, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26337738

ABSTRACT

Rotavirus infection is the most common cause of severe diarrhea disease in infants and young children worldwide. Vaccination is the only control measure likely to have a significant impact on the incidence of severe disease. Rotavirus vaccines have reduced the burden of disease in the United States and Europe and vaccine programs are being introduced in Asia and Africa where it is hoped that vaccine will have significant impact on severe infection. Long-term monitoring and strain surveillance are needed to assess the effects of rotavirus immunization programs and to determine whether changes in strain ecology will affect rotavirus vaccine effectiveness.


Subject(s)
Rotavirus Infections/epidemiology , Rotavirus Infections/prevention & control , Africa/epidemiology , Asia/epidemiology , Child , Child, Preschool , Europe/epidemiology , Humans , Immunity, Herd , Immunization Programs , Incidence , Infant , Rotavirus/immunology , Rotavirus Infections/immunology , Rotavirus Vaccines/administration & dosage , Treatment Outcome , United States/epidemiology
13.
N Engl J Med ; 372(10): 933-43, 2015 Mar 05.
Article in English | MEDLINE | ID: mdl-25738669

ABSTRACT

BACKGROUND: The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time. METHODS: We conducted a randomized, placebo-controlled trial of valganciclovir therapy in neonates with symptomatic congenital CMV disease, comparing 6 months of therapy with 6 weeks of therapy. The primary end point was the change in hearing in the better ear ("best-ear" hearing) from baseline to 6 months. Secondary end points included the change in hearing from baseline to follow-up at 12 and 24 months and neurodevelopmental outcomes, with each end point adjusted for central nervous system involvement at baseline. RESULTS: A total of 96 neonates underwent randomization, of whom 86 had follow-up data at 6 months that could be evaluated. Best-ear hearing at 6 months was similar in the 6-month group and the 6-week group (2 and 3 participants, respectively, had improvement; 36 and 37 had no change; and 5 and 3 had worsening; P=0.41). Total-ear hearing (hearing in one or both ears that could be evaluated) was more likely to be improved or to remain normal at 12 months in the 6-month group than in the 6-week group (73% vs. 57%, P=0.01). The benefit in total-ear hearing was maintained at 24 months (77% vs. 64%, P=0.04). At 24 months, the 6-month group, as compared with the 6-week group, had better neurodevelopmental scores on the Bayley Scales of Infant and Toddler Development, third edition, on the language-composite component (P=0.004) and on the receptive-communication scale (P=0.003). Grade 3 or 4 neutropenia occurred in 19% of the participants during the first 6 weeks. During the next 4.5 months of the study, grade 3 or 4 neutropenia occurred in 21% of the participants in the 6-month group and in 27% of those in the 6-week group (P=0.64). CONCLUSIONS: Treating symptomatic congenital CMV disease with valganciclovir for 6 months, as compared with 6 weeks, did not improve hearing in the short term but appeared to improve hearing and developmental outcomes modestly in the longer term. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT00466817.).


Subject(s)
Antiviral Agents/administration & dosage , Cytomegalovirus Infections/congenital , Cytomegalovirus Infections/drug therapy , Ganciclovir/analogs & derivatives , Hearing Loss, Sensorineural/prevention & control , Antiviral Agents/adverse effects , Audiometry , Child Development , Cytomegalovirus Infections/complications , Double-Blind Method , Drug Administration Schedule , Evoked Potentials, Auditory, Brain Stem , Ganciclovir/administration & dosage , Ganciclovir/adverse effects , Gestational Age , Hearing Loss, Sensorineural/virology , Humans , Infant, Newborn , Neutropenia/chemically induced , Valganciclovir
14.
Hum Vaccin Immunother ; 10(8): 2267-75, 2014.
Article in English | MEDLINE | ID: mdl-25424931

ABSTRACT

During the vaccination phase of the Rotavirus Efficacy and Safety Trial (REST), the period between the administration of dose 1 through 13 days after the administration of dose 3, there were more wild-type rotavirus gastroenteritis (RVGE) cases among vaccine recipients compared with placebo recipients using the protocol-specified microbiological plaque assay in the clinical-efficacy cohort, a subset of subjects where vaccine efficacy against RVGE of any severity was assessed. In this study, a rotavirus genome segment 6-based reverse transcriptase-polymerase chain reaction assay was applied post hoc to clarify the accuracy of type categorization of all these RVGE cases in vaccine recipients during the vaccination phase of REST. The assay characterized 147 (90%) of 163 re-assayed RVGE cases or rotavirus-associated health care contacts as type-determinable: either wild-type or vaccine-type rotavirus strains. In the clinical-efficacy cohort (N = 5673), 19 (18.8%) of 101 samples from RVGE cases contained wild-type rotavirus, 70 (69.3%) vaccine virus, and 12 (11.9%) were indeterminable. In the large-scale cohort (N = 68,038), 10 (34.5%) of 29 samples from RVGE-related health care contacts contained wild-type rotavirus strains, 15 (51.7%) vaccine-type rotavirus strains, and 4 (13.8%) were indeterminable. Of the 33 samples from RVGE cases in placebo recipients, all were confirmed to contain wild-type rotaviruses. Altogether, this post-hoc re-evaluation showed that the majority (75%) of type-determinable RVGE cases or health care contacts that occurred during the vaccination phase of REST in vaccine recipients were associated with vaccine-type rotavirus strains rather than wild-type rotavirus strains.


Subject(s)
Gastroenteritis/virology , Polymerase Chain Reaction , Rotavirus Infections/virology , Rotavirus Vaccines/administration & dosage , Rotavirus Vaccines/adverse effects , Rotavirus/classification , Rotavirus/isolation & purification , Gastroenteritis/prevention & control , Genotype , Humans , Infant , RNA, Viral/genetics , Rotavirus/genetics , Rotavirus Infections/prevention & control
15.
Pediatr Infect Dis J ; 32(8): 863-70, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23584581

ABSTRACT

BACKGROUND: Live oral rotavirus vaccines have been less immunogenic and efficacious for children of developing countries than for those in middle income and industrialized countries, and the basis for these differences is not fully understood. Recently, we demonstrated that breastmilk from mothers in India had significantly higher IgA and neutralizing activity against rotavirus that could reduce the effective titer of rotavirus vaccines reaching the gut when compared with that from mothers in the United States. We extended our study to understand the specific contribution of those nonantibody components in breastmilk to the neutralizing activity against rotavirus vaccine we observed. METHODS: Breastmilk samples were collected from mothers of breast-feeding infants aged between 4 and 29 weeks (ie, vaccine eligible age) in India (N = 40), South Africa (N = 50) and the United States (N = 51). We examined breastmilk for lactoferrin, lactadherin, rotavirus-specific IgA and neutralizing activity against 3 rotavirus vaccine strains (Rotarix, RotaTeq G1 and 116E) using enzyme immunoassays, a plaque reduction assay or a microneutralization assay. RESULTS: We observed higher levels of lactoferrin, lactadherin, IgA and neutralizing activity in breastmilk specimens from Indian and South African women than those from American women. We demonstrated positive associations between levels of lactoferrin or IgA and neutralizing activity in Indian and South African specimens, but not in American specimens. We demonstrated that the inhibitory effect of lactoferrin was dose- or species-dependent, as evidenced by greater reduction in titer of Rotarix and 116E by human lactoferrin. Lactadherin also exhibited inhibitory activity to rotavirus vaccines but appeared to be less effective. CONCLUSIONS: The lower immunogenicity and efficacy of rotavirus vaccines in developing countries could be explained, in part, by synergistic inhibitory effect of high levels of antibody and nonantibody components in breastmilk consumed by infants at the time of immunization. Therefore, there is a need for alternative rotavirus vaccine strategies in breast-feeding populations.


Subject(s)
Antibodies, Viral/immunology , Milk Proteins/immunology , Milk, Human/drug effects , Milk, Human/immunology , Rotavirus Vaccines/administration & dosage , Rotavirus/immunology , Adolescent , Adult , Antibodies, Neutralizing/analysis , Antibodies, Neutralizing/immunology , Antibodies, Viral/analysis , Developed Countries/statistics & numerical data , Developing Countries/statistics & numerical data , Female , Humans , Immunoglobulin A/analysis , Immunoglobulin A/immunology , India , Milk Proteins/analysis , Milk, Human/chemistry , Neutralization Tests , Regression Analysis , South Africa , Statistics, Nonparametric , United States
16.
Curr Infect Dis Rep ; 15(3): 242-50, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23526488

ABSTRACT

Rotavirus infection is the most common cause of severe diarrhea disease in infants and young children worldwide and continues to have a major global impact on childhood morbidity and mortality. No antiviral therapy is available. Treatment of rotavirus gastroenteritis is limited to rehydration therapy. Recently, therapies, such as probiotics, have been developed as adjuncts to rehydration therapy. Two effective rotavirus vaccines are available and recommended for routine immunization of all infants. These vaccines have been introduced in both developed and developing countries. As rotavirus vaccines are implemented, studies that assess health impact, indirect benefits, and strain changes after the introduction of rotavirus vaccine have been reported. In the United States, rotavirus vaccination has led to dramatic drops in severe rotavirus-related hospitalizations and has reduced emergency room visits. Herd immunity has also been noted after routine rotavirus immunization. There have been no significant strain shifts or escape mutants noted since the introduction of rotavirus vaccines.

17.
J Pediatric Infect Dis Soc ; 2(2): 93-6, 2013 Jun.
Article in English | MEDLINE | ID: mdl-26619456
18.
Adv Pediatr ; 59(1): 47-74, 2012.
Article in English | MEDLINE | ID: mdl-22789574

ABSTRACT

Rotavirus infection is the most common cause of severe diarrhea disease in infants and young children worldwide and continues to have a major global impact on childhood morbidity and mortality. Vaccination is the only control measure likely to have a significant impact on the incidence of severe dehydrating rotavirus disease. Rotavirus vaccines have reduced the burden of rotavirus disease in the United States. Long-term monitoring will need to continue to assess the effects of rotavirus immunization programs and epidemiologic strain surveillance is necessary to determine whether changes in strain ecology will affect the rotavirus vaccine effectiveness and whether rotaviruses with the ability to evade vaccine immunity emerge.


Subject(s)
Diarrhea/therapy , Rotavirus Infections , Rotavirus Vaccines , Rotavirus/immunology , Child, Preschool , Contraindications , Diarrhea/prevention & control , Diarrhea/virology , Humans , Immunity, Herd/drug effects , Infant , Rotavirus/classification , Rotavirus Infections/epidemiology , Rotavirus Infections/prevention & control , Rotavirus Infections/therapy , Rotavirus Vaccines/administration & dosage , United States/epidemiology
19.
Curr Opin Pediatr ; 24(1): 76-84, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22189398

ABSTRACT

PURPOSE OF REVIEW: Rotavirus infection is the most common cause of severe diarrhea disease in infants and young children worldwide and continues to have a major global impact on childhood morbidity and mortality. Two effective rotavirus vaccines are available and recommended for routine immunization of all infants. These vaccines have been introduced in both developed and developing countries. As rotavirus vaccines are implemented, studies have been undertaken that assess the effects of vaccination on rotavirus disease in children. This review summarizes the results of these studies. RECENT FINDINGS: Studies that assess health impact, indirect benefits, and strain changes after the introduction of rotavirus vaccine have been reported. In industrialized countries, rotavirus vaccination has led to dramatic drops in severe rotavirus-related hospitalizations and has reduced emergency room visits. Data from clinical trials in developing counties in Asia and Africa have demonstrated that rotavirus vaccines significantly reduce severe diarrhea episodes due to rotavirus. Herd (community) immunity has also been noted after routine rotavirus immunization in several countries. There have been no significant strain shifts or escape mutants noted since the introduction of rotavirus vaccines. SUMMARY: Two well tolerated and effective rotavirus vaccines have reduced the health burden of rotavirus gastroenteritis in both developed and developing countries.


Subject(s)
Hospitalization/statistics & numerical data , Immunization Programs , Rotavirus Infections/prevention & control , Rotavirus Vaccines/administration & dosage , Rotavirus/immunology , Child , Child, Preschool , Developed Countries/statistics & numerical data , Developing Countries/statistics & numerical data , Diarrhea/epidemiology , Diarrhea/prevention & control , Diarrhea/virology , Female , Humans , Immunity, Herd , Infant , Infant, Newborn , Male , Public Health , Rotavirus Infections/epidemiology , Rotavirus Vaccines/immunology , Sentinel Surveillance , Treatment Outcome
20.
J Pediatric Infect Dis Soc ; 1(3): 212-22, 2012 Sep.
Article in English | MEDLINE | ID: mdl-26619409

ABSTRACT

BACKGROUND: Human metapneumovirus (HMPV) is a significant cause of respiratory tract infections. Little is known about HMPV in children who are at high risk for lower respiratory tract infection (LRTI). METHODS: To determine the prevalence of HMPV in high-risk children and to identify HMPV risk factors, children ≤24 months with prematurity, chronic lung disease, and/or congenital cardiac disease who were hospitalized with LRTI were prospectively enrolled. Nasopharyngeal aspirates were tested for HMPV, respiratory syncytial virus (RSV), influenza A and B, and parainfluenza types 1-3. Demographics, medical history, and outcomes for those with HMPV and RSV were compared. A multivariate analysis was performed to determine HMPV risk factors. RESULTS: Over 4 years, 1126 eligible children were enrolled. Pathogens were identified in 61% of subjects. HMPV was identified in 9.0%, second to RSV (45%). Coinfection with HMPV and RSV occurred in <1% of subjects. Subjects infected with HMPV were older (8.2 vs 4.0 months, P < .001), were born more prematurely (27 vs 33 weeks, P < .001), and more commonly had chronic lung disease (59.3% vs 21.8%, P < .001) compared with subjects infected with RSV. In a multivariate analysis that compared children infected with HMPV to all others, increasing age and household exposure to children ages 6-12 were associated with an increased risk, whereas birth at older gestational age and exposure to children age >12 were associated with a decreased risk. CONCLUSIONS: HMPV was detected in 9% of high-risk children who were hospitalized with lower respiratory tract disease, representing the second most common virus in this population. Compared with all other subjects (including RSV-infected), subjects infected with HMPV were older but were born more prematurely.

SELECTION OF CITATIONS
SEARCH DETAIL
...